Breaking News

Wednesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
KalVista reports Q4 EPS (37c), consensus (65c) » 07:06
07/01/20
07/01
07:06
07/01/20
07:06
KALV

KalVista

$12.00 /

-0.66 (-5.21%)

Reports Q4 revenue…

Reports Q4 revenue $3.82M, consensus $1.66M. "We have two oral candidates in clinical trials that have the potential to provide HAE patients with a complete set of options to treat their disease," said Andrew Crockett, CEO of KalVista. "We are pleased with our progress with the formulation work for KVD824 to deliver a twice-daily treatment for prevention of HAE attacks. Subjects have begun dosing with these new formulations to obtain additional pharmacokinetic and pharmacodynamic data, and we look forward to providing these data later this year in advance of starting a Phase 2 clinical trial. Patients also continue to be treated in our Phase 2 clinical trial for KVD900 as an on-demand therapy, and we expect data from that trial in the second half of this year."

ShowHide Related Items >><<
KALV KalVista
$12.00 /

-0.66 (-5.21%)

KALV KalVista
$12.00 /

-0.66 (-5.21%)

06/15/20
Fly Intel: Top five analyst initiations
06/15/20 H.C. Wainwright
KalVista initiated with a Buy at H.C. Wainwright
03/10/20 Roth Capital
Roth Capital sees good odds for KalVista into Q2 KVD900 readout
01/13/20 Roth Capital
KalVista update suggests management's confidence in study, says Roth Capital
KALV KalVista
$12.00 /

-0.66 (-5.21%)

Over a week ago
Initiation
Fly Intel: Top five analyst initiations » 10:06
06/15/20
06/15
10:06
06/15/20
10:06
SBUX

Starbucks

$75.02 /

-1.36 (-1.78%)

, KALV

KalVista

$10.61 /

+0.205 (+1.97%)

, SYNA

Synaptics

$61.41 /

-1.19 (-1.90%)

, TRNS

Transcat

$24.84 /

-0.67 (-2.63%)

, IP

International Paper

$33.95 /

-0.98 (-2.81%)

Catch up on today's…

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Starbucks (SBUX) initiated with an Overweight at Atlantic Equities. 2. KalVista (KALV) initiated with a Buy at H.C. Wainwright. 3. Synaptics (SYNA) initiated with a Neutral at Rosenblatt. 4. Transcat (TRNS) initiated with a Buy at B. Riley FBR. 5. International Paper (IP) initiated with an Underweight at Morgan Stanley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
TRNS Transcat
$24.84 /

-0.67 (-2.63%)

SYNA Synaptics
$61.41 /

-1.19 (-1.90%)

SBUX Starbucks
$75.02 /

-1.36 (-1.78%)

KALV KalVista
$10.61 /

+0.205 (+1.97%)

IP International Paper
$33.95 /

-0.98 (-2.81%)

SBUX Starbucks
$75.02 /

-1.36 (-1.78%)

06/15/20 Atlantic Equities
Starbucks initiated with an Overweight at Atlantic Equities
06/11/20
Fly Intel: Top five analyst downgrades
06/11/20 BMO Capital
Starbucks update confirms expectation of prolonged recovery, says BMO Capital
06/11/20 KeyBanc
Starbucks downgraded to Sector Weight at KeyBanc
KALV KalVista
$10.61 /

+0.205 (+1.97%)

06/15/20 H.C. Wainwright
KalVista initiated with a Buy at H.C. Wainwright
03/10/20 Roth Capital
Roth Capital sees good odds for KalVista into Q2 KVD900 readout
01/13/20 Roth Capital
KalVista update suggests management's confidence in study, says Roth Capital
12/10/19 Needham
KalVista price target lowered to $28 from $35 at Needham
SYNA Synaptics
$61.41 /

-1.19 (-1.90%)

06/15/20 Rosenblatt
Synaptics initiated with a Neutral at Rosenblatt
06/08/20 KeyBanc
iPhone sell-through improves modestly as stores begin to reopen, says KeyBanc
05/04/20 KeyBanc
Apple cautious iPhone outlook likely a headwind for chip suppliers, says KeyBanc
03/31/20 KeyBanc
Synaptics downgraded to Sector Weight at KeyBanc
TRNS Transcat
$24.84 /

-0.67 (-2.63%)

06/15/20 B. Riley FBR
Transcat initiated with a Buy at B. Riley FBR
06/15/20 B. Riley FBR
Transcat initiated with a Buy at B. Riley FBR
03/03/20
LD Micro to hold a virtual conference
01/15/20 Sidoti
Transcat initiated with a Buy at Sidoti
IP International Paper
$33.95 /

-0.98 (-2.81%)

06/15/20 Morgan Stanley
Packaging Corp. initiated with an Equal Weight at Morgan Stanley
06/15/20 Morgan Stanley
International Paper initiated with an Underweight at Morgan Stanley
05/26/20 Deutsche Bank
International Paper price target lowered to $40 from $46 at Deutsche Bank
04/09/20 KeyBanc
International Paper price target lowered to $29 from $38 at KeyBanc
TRNS Transcat
$24.84 /

-0.67 (-2.63%)

SYNA Synaptics
$61.41 /

-1.19 (-1.90%)

SBUX Starbucks
$75.02 /

-1.36 (-1.78%)

KALV KalVista
$10.61 /

+0.205 (+1.97%)

IP International Paper
$33.95 /

-0.98 (-2.81%)

SBUX Starbucks
$75.02 /

-1.36 (-1.78%)

SYNA Synaptics
$61.41 /

-1.19 (-1.90%)

SBUX Starbucks
$75.02 /

-1.36 (-1.78%)

SBUX Starbucks
$75.02 /

-1.36 (-1.78%)

IP International Paper
$33.95 /

-0.98 (-2.81%)

Initiation
KalVista initiated with a Buy at H.C. Wainwright » 06:08
06/15/20
06/15
06:08
06/15/20
06:08
KALV

KalVista

$10.40 /

+0.24 (+2.36%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Andrew Fein initiated coverage of KalVista Pharmaceuticals with a Buy rating and $30 price target. The analyst likes KalVista's kallikrein inhibitor platform, which is initially targeting hereditary angioedema treatment along with development in diabetic macular edema.

ShowHide Related Items >><<
KALV KalVista
$10.40 /

+0.24 (+2.36%)

KALV KalVista
$10.40 /

+0.24 (+2.36%)

03/10/20 Roth Capital
Roth Capital sees good odds for KalVista into Q2 KVD900 readout
01/13/20 Roth Capital
KalVista update suggests management's confidence in study, says Roth Capital
12/10/19 Needham
KalVista price target lowered to $28 from $35 at Needham
12/09/19 Roth Capital
Roth says KalVista trial results have 'silver lining' despite endpoint miss
KALV KalVista
$10.40 /

+0.24 (+2.36%)

Over a month ago
Hot Stocks
KalVista announces potential impact of COVID-19 on operations » 07:04
04/07/20
04/07
07:04
04/07/20
07:04
KALV

KalVista

$7.52 /

-0.12 (-1.57%)

KalVista announced…

KalVista announced potential impact of COVID-19 on its ongoing operations and provided revised financial guidance that activities are funded into at least early 2022. KVD900 is being developed as an on-demand oral therapy for the treatment of HAE attacks. The ongoing Phase 2 trial is being conducted in approximately 20 sites in Europe and the U.S. and is a placebo-controlled, crossover study designed to evaluate the safety and efficacy of KVD900. Patients in the study treat a total of two eligible attacks, taking the medication at home after a telephone consultation with the investigator to confirm eligibility of the attack. Patients do not need to treat sequential attacks, and the intermittent dosing regimen allows those whose participation is paused by the ongoing crisis to remain active in the study and resume dosing as it becomes appropriate. The data collected to date is not affected by any potential delays and will contribute to final study outcomes as originally planned. The clinical trial remains active and KalVista is working with investigators and patients to enable them to continue their participation under the evolving circumstances as appropriate in each geographic region, given the ongoing health response to the pandemic. KalVista previously announced that the company's cash and cash equivalents at January 31, were $80.5M and were sufficient to fund operations into 2021. Due to the ongoing pandemic, the company has adjusted its plans and now anticipates that the current cash balance can fund operations into at least early 2022, without significantly impacting the timing of its development activities for either KVD900 or KVD824. The company continues to monitor events closely and will further adjust its spending plan to extend the duration of its cash runway if warranted.

ShowHide Related Items >><<
KALV KalVista
$7.52 /

-0.12 (-1.57%)

03/10/20 Roth Capital
Roth Capital sees good odds for KalVista into Q2 KVD900 readout
01/13/20 Roth Capital
KalVista update suggests management's confidence in study, says Roth Capital
12/10/19 Needham
KalVista price target lowered to $28 from $35 at Needham
12/09/19 Roth Capital
Roth says KalVista trial results have 'silver lining' despite endpoint miss
Over a quarter ago
Recommendations
Roth Capital sees good odds for KalVista into Q2 KVD900 readout » 12:10
03/10/20
03/10
12:10
03/10/20
12:10
KALV

KalVista

$11.30 /

-0.8 (-6.61%)

The Phase 2 study readout…

The Phase 2 study readout for KVD900 in Q2 for the on-demand treatment of hereditary angioedema should be a major catalyst for shares of KalVista Pharmaceuticals, Roth Capital analyst Zegbeh Jallah tells investors in a post-earnings research note. The analyst views HAE as a "significant market opportunity" for KalVista, and believes the "odds are good" heading into the data readout. Furter, KalVista is in a strong financial position to execute, says Jallah, who keeps a Buy rating on the shares with a $30 price target.

ShowHide Related Items >><<
KALV KalVista
$11.30 /

-0.8 (-6.61%)

01/13/20 Roth Capital
KalVista update suggests management's confidence in study, says Roth Capital
12/10/19 Needham
KalVista price target lowered to $28 from $35 at Needham
12/09/19 Roth Capital
Roth says KalVista trial results have 'silver lining' despite endpoint miss
10/14/19 Roth Capital
Ophthalmic therapies 'could go from 0 to 100 real quick,' says Roth Capital
Earnings
KalVista reports Q3 EPS (52c), consensus (26c) » 07:35
03/10/20
03/10
07:35
03/10/20
07:35
KALV

KalVista

$12.10 /

-1.01 (-7.70%)

Reports Q3 revenue…

Reports Q3 revenue $1.58M, consensus $11.42M. "Our work to bring multiple best-in-class oral therapies to patients with hereditary angioedema is advancing well," said Andrew Crockett, CEO of KalVista. "First, we look forward to delivering data in the second quarter of this year from our Phase 2 clinical trial with KVD900, our on-demand therapy for HAE attacks. We believe KVD900 has the potential to offer patients an attractive option for control of their disease through a fast-acting tablet that can be taken at the earliest stages of an incipient attack. Second, we continue to make progress in our optimization of KVD824 as a potential oral prophylactic treatment. We still plan to initiate a Phase 2 trial of KVD824 for prophylaxis of HAE attacks in the second half of the year."

ShowHide Related Items >><<
KALV KalVista
$12.10 /

-1.01 (-7.70%)

01/13/20 Roth Capital
KalVista update suggests management's confidence in study, says Roth Capital
12/10/19 Needham
KalVista price target lowered to $28 from $35 at Needham
12/09/19 Roth Capital
Roth says KalVista trial results have 'silver lining' despite endpoint miss
10/14/19 Roth Capital
Ophthalmic therapies 'could go from 0 to 100 real quick,' says Roth Capital
Hot Stocks
KalVista discloses expiration of agreement on KVD001 with Merck » 16:32
02/10/20
02/10
16:32
02/10/20
16:32
KALV

KalVista

$15.65 /

+0.06 (+0.38%)

, MRK

Merck

$85.67 /

+0.58 (+0.68%)

KalVista (KALV) announced…

KalVista (KALV) announced that the option agreement between KalVista and Merck (MRK) related to intravitreal diabetic macular edema candidate KVD001 and future oral DME molecules has expired. Under the terms of the option agreement, Merck paid a $37 million non-refundable upfront fee to KalVista. This agreement with Merck only covered the investigational intravitreal candidate, KVD001, and future oral plasma kallikrein inhibitor programs for DME. With the option expiration, KalVista has no obligations to Merck, and retains full ownership of all of its DME intellectual property in addition to its oral hereditary angioedema portfolio. KalVista intends to continue to aggressively pursue its efforts to develop multiple best-in-class oral plasma kallikrein therapies for HAE, as well as additional programs focused on other proteases.

ShowHide Related Items >><<
KALV KalVista
$15.65 /

+0.06 (+0.38%)

01/13/20 Roth Capital
KalVista update suggests management's confidence in study, says Roth Capital
12/10/19 Needham
KalVista price target lowered to $28 from $35 at Needham
12/09/19 Roth Capital
Roth says KalVista trial results have 'silver lining' despite endpoint miss
10/14/19 Roth Capital
Ophthalmic therapies 'could go from 0 to 100 real quick,' says Roth Capital
MRK Merck
$85.67 /

+0.58 (+0.68%)

02/06/20 RBC Capital
Merck price target lowered to $92 from $99 at RBC Capital
02/06/20 Maxim
Armata Pharmaceuticals initiated with a Buy at Maxim
01/07/20
Fly Intel: Top five analyst initiations
01/07/20 SVB Leerink
OS miss in 1L SCLC 'a disappointing start to 2020' for Merck, says SVB Leerink
Conference/Events
KalVista management to meet with Roth Capital » 04:55
01/29/20
01/29
04:55
01/29/20
04:55
KALV

KalVista

$16.48 /

-0.05 (-0.30%)

Meeting to be held in New…

Meeting to be held in New York on January 29 hosted by Roth Capital.

ShowHide Related Items >><<
KALV KalVista
$16.48 /

-0.05 (-0.30%)

01/13/20 Roth Capital
KalVista update suggests management's confidence in study, says Roth Capital
12/10/19 Needham
KalVista price target lowered to $28 from $35 at Needham
12/09/19 Roth Capital
Roth says KalVista trial results have 'silver lining' despite endpoint miss
10/14/19 Roth Capital
Ophthalmic therapies 'could go from 0 to 100 real quick,' says Roth Capital
Conference/Events
KalVista management to meet with Roth Capital » 06:49
01/24/20
01/24
06:49
01/24/20
06:49
KALV

KalVista

$18.03 /

-0.02 (-0.11%)

Meeting to be held in New…

Meeting to be held in New York on January 29 hosted by Roth Capital.

ShowHide Related Items >><<
KALV KalVista
$18.03 /

-0.02 (-0.11%)

01/13/20 Roth Capital
KalVista update suggests management's confidence in study, says Roth Capital
12/10/19 Needham
KalVista price target lowered to $28 from $35 at Needham
12/09/19 Roth Capital
Roth says KalVista trial results have 'silver lining' despite endpoint miss
10/14/19 Roth Capital
Ophthalmic therapies 'could go from 0 to 100 real quick,' says Roth Capital
Recommendations
KalVista update suggests management's confidence in study, says Roth Capital » 12:26
01/13/20
01/13
12:26
01/13/20
12:26
KALV

KalVista

$15.32 /

+0.09 (+0.59%)

Roth Capital analyst…

Roth Capital analyst Zegbeh Jallah tells investors in a research note that KalVista on Monday provided "exciting" updates on 2020 catalysts, one of which was the specific timing of the data readout of the Phase 2 study of KVD900 for the on-demand treatment of Hereditary Angioedema in the second quarter, which she says is suggestive of management's confidence in the study's progress. As a further sign of that confidence, Jallah says management also announced that its next-gen, oral plasma kallikrein inhibitor KVD824 will be used for the prophylactic treatment of HAE, and that study is expected to start during the second half of the year. The analyst made no change to her Buy rating and $30 price target.

ShowHide Related Items >><<
KALV KalVista
$15.32 /

+0.09 (+0.59%)

12/10/19 Needham
KalVista price target lowered to $28 from $35 at Needham
12/09/19 Roth Capital
Roth says KalVista trial results have 'silver lining' despite endpoint miss
10/14/19 Roth Capital
Ophthalmic therapies 'could go from 0 to 100 real quick,' says Roth Capital
08/19/19 Cantor Fitzgerald
KalVista's 2H could be 'tranformational' for PKal-inhib, says Cantor Fitzgerald

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.